Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Hyundai Motor Union Launches First Full Strike in Decade Over Wages, AI Job Risks 
Samsung Shares Rise on $72 Billion Shareholder Return Plan 
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth 
Moody’s Upgrades Vodafone Hybrid Debt Ratings to Baa3 
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
Welspun Corp Shares Hit Record High on $1.8 Billion U.S. Order 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
REPAY Stock Rises After Visa Platform Connect Collaboration 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
Toyota, Honda Shares Rise on Possible U.S.-Canada Auto Tariff Cut 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Coty Revenue Beats Estimates as Beauty Demand Holds Firm 
Anthropic Eyes $10B-Plus Credit Line Ahead of Potential IPO 
Add as a preferred source on Google
SOUTH SAN FRANCISCO, Calif., May 07, 2018 -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platform, will present at the Bank of America Merrill Lynch 2018 Health Care Conference. Sean McCarthy, D.Phil., president and chief executive officer will deliver a corporate overview on May 17, 2018, at 10:40 a.m. P.T./ 1:40 p.m. ET.
A live audio webcast of the presentation will be available through the Investors and News section of CytomX's website. An archived replay will be available for 90 days following the event.
About CytomX Therapeutics
CytomX Therapeutics is a clinical-stage stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody therapeutic technology platform. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company’s pipeline includes cancer immunotherapies against clinically-validated targets, such as CX-072, a PD-L1-targeting Probody therapeutic, BMS-986249, a CTLA-4-targeting Probody therapeutic, CX-188, a PD-1-targeting Probody therapeutic, and first-in-class Probody drug conjugates against highly attractive targets, such as CX-2009, a CD166-targeting Probody drug conjugate and CX-2029, a CD71-targeting Probody drug conjugate, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company, Pfizer and ImmunoGen, Inc. For more information, visit www.cytomx.com or follow us on Twitter.
CytomX Therapeutics
Christopher Keenan
VP, Investor Relations and Corporate Communications
[email protected]
650-383-0823
